Current and historical daily PE Ratio for Adocia (
) from 2013 to May 16 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Adocia stock (ADOIF) PE ratio as of May 16 2024 is 0.
More Details
Adocia (ADOIF) PE Ratio (TTM) Chart
Adocia (ADOIF) PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
Total 1078
- 1
- 2
- 3
- 4
- 5
- 6
- 12
| Adocia PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-16 | At Loss | 2023-08-07 | At Loss |
| 2023-10-09 | At Loss | 2023-08-04 | At Loss |
| 2023-10-06 | At Loss | 2023-08-03 | At Loss |
| 2023-10-05 | At Loss | 2023-08-02 | At Loss |
| 2023-10-04 | At Loss | 2023-08-01 | At Loss |
| 2023-10-03 | At Loss | 2023-07-31 | At Loss |
| 2023-10-02 | At Loss | 2023-07-28 | At Loss |
| 2023-09-29 | At Loss | 2023-07-27 | At Loss |
| 2023-09-28 | At Loss | 2023-07-26 | At Loss |
| 2023-09-27 | At Loss | 2023-07-25 | At Loss |
| 2023-09-26 | At Loss | 2023-07-24 | At Loss |
| 2023-09-25 | At Loss | 2023-07-21 | At Loss |
| 2023-09-22 | At Loss | 2023-07-20 | At Loss |
| 2023-09-21 | At Loss | 2023-07-19 | At Loss |
| 2023-09-20 | At Loss | 2023-07-18 | At Loss |
| 2023-09-19 | At Loss | 2023-07-17 | At Loss |
| 2023-09-18 | At Loss | 2023-07-14 | At Loss |
| 2023-09-15 | At Loss | 2023-07-13 | At Loss |
| 2023-09-14 | At Loss | 2023-07-12 | At Loss |
| 2023-09-13 | At Loss | 2023-07-11 | At Loss |
| 2023-09-12 | At Loss | 2023-07-10 | At Loss |
| 2023-09-11 | At Loss | 2023-07-07 | At Loss |
| 2023-09-08 | At Loss | 2023-07-06 | At Loss |
| 2023-09-07 | At Loss | 2023-07-05 | At Loss |
| 2023-09-06 | At Loss | 2023-06-30 | At Loss |
| 2023-09-05 | At Loss | 2023-06-29 | At Loss |
| 2023-09-01 | At Loss | 2023-06-28 | At Loss |
| 2023-08-31 | At Loss | 2023-06-27 | At Loss |
| 2023-08-30 | At Loss | 2023-06-26 | At Loss |
| 2023-08-29 | At Loss | 2023-06-23 | At Loss |
| 2023-08-28 | At Loss | 2023-06-22 | At Loss |
| 2023-08-25 | At Loss | 2023-06-21 | At Loss |
| 2023-08-24 | At Loss | 2023-06-20 | At Loss |
| 2023-08-23 | At Loss | 2023-06-16 | At Loss |
| 2023-08-22 | At Loss | 2023-06-15 | At Loss |
| 2023-08-21 | At Loss | 2023-06-14 | At Loss |
| 2023-08-18 | At Loss | 2023-06-13 | At Loss |
| 2023-08-17 | At Loss | 2023-06-12 | At Loss |
| 2023-08-16 | At Loss | 2023-06-09 | At Loss |
| 2023-08-15 | At Loss | 2023-06-08 | At Loss |
| 2023-08-14 | At Loss | 2023-06-07 | At Loss |
| 2023-08-11 | At Loss | 2023-06-06 | At Loss |
| 2023-08-10 | At Loss | 2023-06-05 | At Loss |
| 2023-08-09 | At Loss | 2023-06-02 | At Loss |
| 2023-08-08 | At Loss | 2023-06-01 | At Loss |
Adocia (ADOIF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Adocia
NAICS : 325412
ISIN : FR0011184241
Compare
Compare
Traded in other countries / regions
ADOC.FranceA89.Germany0QAI.UKADOIF.USA IPO Date
2013-04-23Description
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers